静脉-静脉体外膜氧合用于急性COVID-19相关呼吸衰竭患者的比较效果研究
该观察性研究覆盖五大洲30个国家、2020年1月3日至2021年8月29日期间7345例因疑似或实验室确诊SARS-CoV-2感染入住ICU的成人。研究比较PaO2/FiO2<80 mmHg时采用ECMO与常规机械通气(不用ECMO)对结局的影响,主要终点为入住ICU后60天内住院死亡率,采用边际结构模型联合逆概率加权进行依从性校正,并考虑竞争事件及基线与时变混杂。结果显示,844/7345例(11.5%)在随访期间任一时间点接受ECMO;包含ECMO的治疗策略校正死亡率为26.0%(95%CI 24.5%–27.5%),常规治疗为33.2%(95%CI 31.8%–34.6%),风险差-7.1%(95%CI -8.2%–-6.1%),风险比0.78(95%CI 0.75–0.82)。亚组分析提示,ECMO在年龄<65岁、PaO2/FiO2<80 mmHg或机械通气前10天驱动压>15 cmH2O的患者中效果最明显。作者认为年龄、低氧血症严重程度及机械通气时长与强度是疗效修饰因素,决定是否启动ECMO时应予考虑。
要点
- 在PaO2/FiO2<80 mmHg的COVID-19相关呼吸衰竭成人中,包含ECMO的治疗策略60天住院死亡率26.0%(95%CI 24.5%–27.5%),常规机械通气为33.2%(95%CI 31.8%–34.6%),风险差-7.1%(95%CI -8.2%–-6.1%),RR 0.78(95%CI 0.75–0.82)。
- 7345例ICU成人中844例(11.5%)在随访期间任一时刻接受ECMO。
- 亚组分析提示ECMO在年龄<65岁、PaO2/FiO2<80 mmHg或机械通气前10天驱动压>15 cmH2O的患者中效果最明显。
- 作者认为年龄、低氧血症严重程度及机械通气时长与强度是疗效修饰因素,决定启动ECMO时应予考虑。
适用人群与场景
- 五大洲30个国家、2020年1月3日至2021年8月29日期间入住ICU的7345例成人,临床疑似或实验室确诊SARS-CoV-2感染。
- 干预组为PaO2/FiO2<80 mmHg时接受ECMO的患者;对照组为未接受ECMO的常规机械通气患者。
诊断标准与关键阈值
- ECMO启动参考阈值:PaO2/FiO2<80 mmHg。
研究设计与关键结果
- 研究类型为观察性比较效果研究,覆盖30个国家,纳入7345例成人,比较PaO2/FiO2<80 mmHg时ECMO与常规机械通气(不用ECMO)的结局。
- 844/7345例(11.5%)在随访期间任一时刻接受ECMO。
- 主要终点为入住ICU后60天内住院死亡率:包含ECMO的治疗策略依从性校正死亡率为26.0%(95%CI 24.5%–27.5%),常规治疗为33.2%(95%CI 31.8%–34.6%),风险差-7.1%(95%CI -8.2%–-6.1%),风险比0.78(95%CI 0.75–0.82)。
- 亚组分析:ECMO在年龄<65岁、PaO2/FiO2<80 mmHg或机械通气前10天驱动压>15 cmH2O的患者中效果最明显。
- 统计方法:采用边际结构模型联合逆概率加权计算依从性校正估计,并考虑竞争事件及基线与时变混杂。
证据类型、等级与局限
- 证据类型:观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,年龄、低氧血症严重程度及机械通气时长与强度是疗效修饰因素,决定是否启动ECMO时应予考虑。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To estimate the effect of extracorporeal membrane oxygenation (ECMO) compared with conventional mechanical ventilation on outcomes of patients with covid-19 associated respiratory failure.
DESIGN: Observational study.
SETTING: 30 countries across five continents, 3 January 2020 to 29 August 2021.
PARTICIPANTS: 7345 adults admitted to the intensive care unit with clinically suspected or laboratory confirmed SARS-CoV-2 infection.
INTERVENTIONS: ECMO in patients with a partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio <80 mm Hg compared with conventional mechanical ventilation without ECMO.
MAIN OUTCOME MEASURE: The primary outcome was hospital mortality within 60 days of admission to the intensive care unit. Adherence adjusted estimates were calculated using marginal structural models with inverse probability weighting, accounting for competing events and for baseline and time varying confounding.
RESULTS: 844 of 7345 eligible patients (11.5%) received ECMO at any time point during follow-up. Adherence adjusted mortality was 26.0% (95% confidence interval 24.5% to 27.5%) for a treatment strategy that included ECMO if the PaO2/FiO2 ratio decreased <80 mm Hg compared with 33.2% (31.8% to 34.6%) had patients received conventional treatment without ECMO (risk difference -7.1%, 95% confidence interval -8.2% to -6.1%; risk ratio 0.78, 95% confidence interval 0.75 to 0.82). In secondary analyses, ECMO was most effective in patients aged <65 years and with a PaO2/FiO2 <80 mm Hg or with driving pressures >15 cmH2O during the first 10 days of mechanical ventilation.
CONCLUSIONS: ECMO was associated with a reduction in mortality in selected adults with covid-19 associated respiratory failure. Age, severity of hypoxaemia, and duration and intensity of mechanical ventilation were found to be modifiers of treatment effectiveness and should be considered when deciding to initiate ECMO in patients with covid-19.
参考来源
- Urner M, Barnett AG, Bassi GL, et al. Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study. BMJ. 2022. PMID: 35508314. doi:10.1136/bmj-2021-068723
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。